Arcellx climbs on positive trial data for blood cancer cell therapy

Arcellx

09/12/2024 12:02

** Shares of cell therapy developer Arcellx  ACLX.O  rise 8%
to $91.35 premarket
    ** Co says its cell therapy anito-cel showed 97% overall
response rate in a mid-stage trial testing patients with
multiple myeloma, a type of blood cancer 
    ** Overall response rate is the proportion of patients who
have a partial or complete response to the therapy
    ** If approved, anito-cel, developed in partnership with
Gilead  GILD.O , will compete with Johnson & Johnson's  JNJ.N 
cell therapy Carvykti 
    ** Brokerage TD Cowen says anito-cel's efficacy remains at
least as good as Carvykti, but with superior safety 
    ** ACLX's therapy showed no delayed damage to the nervous
system, but three deaths occurred due to adverse events during
the trial
    ** Up to last close, stock up 52.3% YTD

    

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))